¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cutaneous lymphoid hyperplasia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • compensatory hyperplasia
    º¸»ó°ú´ÙÇü¼º
  • complex hyperplasia
    º¹ÇÕÁõ½Ä
  • congenital adrenal hyperplasia
    ¼±ÃµºÎ½Å°ú´ÙÇü¼º, ¼±ÃµÄáÆÏÀ§»ù°ú´ÙÇü¼º
  • cardiac myocyte hyperplasia
    ½ÉÀå±ÙÀ°¼¼Æ÷°ú´ÙÇü¼º
  • endocervical hyperplasia
    Àڱøñ³»¸·°ú´ÙÇü¼º, Àڱðæ°ü³»¸·Áõ½ÄÁõ
  • endometrial hyperplasia
    Àڱ󻸷°ú´ÙÇü¼º, Àڱ󻸷Áõ½Ä(Áõ)
  • essential melanotic mucosal hyperplasia
    º»Å¸á¶ó´ÑÁ¡¸·Áõ½Ä
  • fibromuscular hyperplasia
    ¼¶À¯±ÙÀ°°ú´ÙÇü¼º
  • follicular hyperplasia
    ÅÐÁý°ú´ÙÇü¼º
  • gingival hyperplasia
    ÀÕ¸öÁõ½Ä
  • glandular hyperplasia
    »ùÁ¾Áõ½Ä
  • hyperplasia
    °ú´ÙÇü¼º, °úÇü¼º, Áõ½Ä(Áõ)
  • intravascular papillary endothelial hyperplasia
    Ç÷°ü³»À¯µÎ¸ð¾ç³»ÇǼ¼Æ÷Áõ½Ä
  • intraductal hyperplasia
    °ü³»Áõ½Ä
  • lentiginous melanocytic hyperplasia
    Èæ»öÁ¡¸á¶ó´Ñ¼¼Æ÷Áõ½ÄÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • endometrial hyperplasia
    Àڱ󻸷°ú´ÙÇü¼º, Àڱ󻸷Áõ½ÄÁõ
  • essential melanotic mucosal hyperplasia
    º»ÅÂÁ¡¸·¸á¶ó´ÑÁ¡¸·Áõ½Ä
  • fibromuscular hyperplasia
    ¼¶À¯±ÙÀ°°ú´ÙÇü¼º
  • follicular hyperplasia
    ÅÐÁý°ú´ÙÇü¼º
  • gingival hyperplasia
    ÀÕ¸öÁõ½ÄÁõ
  • glandular hyperplasia
    »ùÁ¾Áõ½Ä
  • hyperplasia
    °ú´ÙÇü¼º, Áõ½Ä(Áõ)
  • intravascular papillary endothelial hyperplasia
    Ç÷°ü³»À¯µÎ¸ð¾ç³»ÇǼ¼Æ÷Áõ½Ä
  • lentiginous melanocytic hyperplasia
    Èæ»öÁ¡¸á¶ó´Ñ¼¼Æ÷Áõ½Ä
  • lipoid adrenal hyperplasia
    ÁöÁúºÎ½Å°ú´ÙÇü¼º
  • nodular hyperplasia
    °áÀý°ú´ÙÇü¼º
  • oral focal v hyperplasia
    ÀԾȱ¹¼Ò»óÇÇÁõ½Ä
  • papillary endothelial hyperplasia
    À¯µÎ¸ð¾ç³»ÇǼ¼Æ÷Áõ½Ä
  • pseudocarcinomatous hyperplasia
    °ÅÁþ¾ÏÁ¾Áõ½Ä
  • pseudoepitheliomatous hyperplasia
    °ÅÁþ»óÇÇÁ¾Áõ½Ä
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • American cutaneous Leishmaniasis
    ¾Æ¸Þ¸®Ä«ÇǺθ®½´¸¶´Ï¾Æº´.
  • Lateral cutaneous branch(of thorax)
    °¡ÂÊ(°¡½¿)ÇǺΰ¡Áö
  • american cutaneous leishmaniasis
    ¾Æ¸Þ¸®Ä«ÇǺθ®½´¸¶´Ï¾Æº´
  • anterior cutaneous branch
    ¾ÕÇǺΰ¡Áö
  • anterior cutaneous branch (of abdomen)
    ¾Õ(¹è)ÇǺΰ¡Áö
  • anterior cutaneous branch (of thorax)
    ¾Õ(°¡½¿)ÇǺΰ¡Áö
  • anterior cutaneous branches
    ¾ÕÇǺΰ¡Áö
  • graft, perichondral cutaneous
    ¿¬°ñ¸·ÇǺÎÀ̽Ä
  • hallucination, cutaneous
    ÇǺÎȯ°¢(ù«Ý±ü³ÊÆ)
  • inferior lateral cutaneous nerve of arm
    ¾Æ·¡°¡ÂÊÀ§ÆÈÇǺνŰæ
  • posterior cutaneous branch
    µÚÇǺΰ¡Áö
  • posterior cutaneous nerve of arm
    µÚÀ§ÆÈÇǺνŰæ
  • posterior cutaneous nerve of forearm
    µÚ¾Æ·¡ÆÈÇǺνŰæ
  • posterior femoral cutaneous nerve
    µÚ³Ò´Ù¸®ÇǺνŰæ
  • primary cutaneous adenocystic carcinoma
    ¿ø¹ß¼º ÇǺΠ¼±³¶Á¾¼º¾Ï
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lymphoid organ
    ¸²ÇÁ¸ð¾ç±â°ü, ¸²ÇÁ¾ç±â°ü(¡­åÆÐïί).
  • lymphoid stem cell
    ¸²ÇÁ¼º ¸ð¼¼Æ÷
  • lymphoid stem cell
    ¸²ÇÁ¼º °£¼¼Æ÷(¡­àõÊÏá¬øà).
  • lymphoid stroma
    ¸²ÇÁ±âÁú(¡­Ðñòõ).
  • lymphoid system differentiation
    ¸²ÇÁ°èºÐÈ­
  • lymphoid tissue
    ¸²ÇÁ¾ç Á¶Á÷
  • lymphoid tissue
    ¸²ÇÁÁ¶Á÷
  • lymphoid wandering cell
    ÇØºÎ¸²ÇÁ¼º À¯ÁÖ¼¼Æ÷(¡­àõë´ñËá¬øà).
  • lymphoma,mucosa-associated lymphoid tissue
    Á¡¸·°ü·Ã ¸²ÇÁÁ¶Á÷(ïÄØ¯Î¼Ö¤ ¡­ðÚòÄ)
  • mucosa-associated lymphoid tissue
    Á¡¸·¿¬°ü¸²ÇÁÁ¶Á÷(¡­æáμ¡­ðÚòÄ)
  • mucous associated lymphoid tissue (MALT)
    Á¡¸· ¿¬°ü¼º ¸²ÇÁÁ¶Á÷
  • peripheral lymphoid organs
    ¸»Ãʸ²ÇÁ°è ±â°ü.
  • peripheral lymphoid system
    ¸»Ãʸ²ÇÁ°è
  • skin-associated lymphoid tissue (SALT)
    ÇǺο¬°ü ¸²ÇÁÁ¶Á÷°è
  • total lymphoid irradiation
    Àü¸²ÇÁÁ¶»ç
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Inferior lateral cutaneous nerve of arm
    ¾Æ·¡°¡ÂÊÀ§ÆÈÇǺνŰæ
    [¿¾ ¿ë¾î] ÇÏ¿ÜÃø»ó¿ÏÇǽŰæ
  • Medial dorsal cutaneous nerve
    ¾ÈÂʹߵîÇǺνŰæ
    [¿¾ ¿ë¾î] ³»ÃøÁ·¹èÇǽŰæ
  • Medial cutaneous nerve of forearm
    ¾ÈÂʾƷ¡ÆÈÇǺνŰæ
    [¿¾ ¿ë¾î] ³»ÃøÀü¿ÏÇǽŰæ
  • Medial cutaneous nerve of arm
    ¾ÈÂÊÀ§ÆÈÇǺνŰæ
    [¿¾ ¿ë¾î] ³»Ãø»ó¿ÏÇǽŰæ
  • Medial sural cutaneous nerve
    ¾ÈÂÊÀåµýÁöÇǺνŰæ
    [¿¾ ¿ë¾î] ³»Ãøºñº¹ÇǽŰæ
  • Medial cutaneous branches of leg
    ¾ÈÂÊÁ¾¾Æ¸®ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ³»ÃøÇÏÅðÇÇÁö
  • Medial cutaneous branch
    ¾ÈÂÊÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ³»ÃøÇÇÁö
  • Anterior cutaneous branch (of thorax)
    ¾Õ(°¡½¿)ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] Àü(Èä)ÇÇÁö
  • Anterior cutaneous branch (of abdomen)
    ¾Õ(¹è)ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] Àü(º¹)ÇÇÁö
  • Anterior cutaneous branch
    ¾ÕÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÀüÇÇÁö
  • Anterior cutaneous branches
    ¾ÕÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÀüÇÇÁö
  • Superior lateral cutaneous nerve of arm
    À§°¡ÂÊÀ§ÆÈÇǺνŰæ
    [¿¾ ¿ë¾î] »ó¿ÜÃø»ó¿ÏÇǽŰæ
  • Intermediate dorsal cutaneous nerve
    Áß°£¹ßµîÇǺνŰæ
    [¿¾ ¿ë¾î] ÁßÁ·¹èÇǽŰæ
  • Cutaneous branch
    ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÇÇÁö
  • Cutaneous branches
    ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÇÇÁö
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MALT Mucosa Associated Lymphoid Tissue
BALT broncho-alveolar lavage fluid; bronchus-associated lymphoid tissue
CTLL cytotoxic lymphoid line
GALT galactose-1-p-uridyltransferase; gut-associated lymphoid tissue
LCL Levinthal-Coles-Lillie [body]; lower confidence limit; lower control limit; lymphoblastoid cell line...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LCL B-lymphoid cell lines
BALT Bronchus-associated Lymphoid tissue
CLL Chronic Lymphoid Leukemia
CALT Conjunctiva-associated lymphoid tissue
GALT Gut associated lymphoid tissue
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dilantin hyperplasia
    µô¶õƾ¼º Ä¡Àº Áõ½Ä
  • fibrous inflammatory hyperplasia
    ¼¶À¯ ¿°Áõ¼º °úÇü¼º
  • focal nodular hyperplasia
    ÃÊÁ¡¼º °áÀý¼º °úÁõ½Ä
    À§ Á¾¾çÀ¸·Î ºÐ·ùµÇ´Â °£ÀÇ °áÀý¼º º´º¯ÀÇ ÇÑ À¯ÇüÀ¸·Î¼­ °ú¿ÀÁ¾¼º ¹ßÀ° °á¼Õ¿¡ ±âÀÎÇÑ ´ÜÀÏ Á¾±«¼º º´º¯À¸·Î ÇØ¼®µÇ°í ÀÖ´Ù. ÀÌ´Â ÁÖ·Î ÇǸ·ÇÏ¿¡ Àß »ý±â°í Å©±â´Â ¼ö cm ³»¿ÜÀÌ¸ç ¾ãÀº ÆÐ¸·¿¡ ÀÇÇÏ¿© ÁÖº¯ °£ Á¶Á÷À¸·ÎºÎÅÍ Àß ±¸ºÐµÈ´Ù. Àý´Ü¸é¿¡¼­ Á¾±«ÀÇ °¡¿îµ¥¿¡ º° ¸ð¾çÀÇ ¹ÝÈç
  • hyperplasia
    ºñÈÄ, Áõ½Ä, °úÇü¼º
    1. ±â´É Ç×ÁøÀ» À¯¹ß½ÃŰ´Â ÀÚ±ØÀ» ¹Þ¾ÒÀ» ¶§, ºÐ¿­ÀÌ °¡´ÉÇÑ ¼¼Æ÷°¡ ¼¼Æ÷ ºÐ¿­·Î ±× ¼ö°¡ Áõ°¡µÇ´Â °ÍÀ» ¸»Çϸç, °á°úÀûÀ¸·Î ±× Á¶Á÷À̳ª Àå±âµµ Ä¿Áö°Ô µÈ´Ù. ¹Ý¸é, ºñ´ë´Â ¼¼Æ÷ÀÇ Áõ½ÄÀÌ ¾øÀÌ ´Ü¼øÈ÷ ¼¼Æ÷ÀÇ Å©±â°¡ Ä¿Áö´Â °æ¿ì¸¦ À̸£´Â ¸»ÀÌ´Ù. 2. Á¤»ó ¼¼Æ÷ ¼ö°¡ Á¤»óÀûÀÎ ¹è¿­ »óÅ·ΠÁõ°¡ÇÏ´Â Á¶Á÷À̳ª ±¸Á¶¹°ÀÇ °ú¹ßÀ°.
  • hyperplasia of coronoid
    ±Ùµ¹±â °úÁõ½Ä
  • idiopathic fibrous gingival hyperplasia
    Ư¹ß¼º ¼¶À¯¼º Ä¡Àº Áõ½Ä
  • inflammatory gingival hyperplasia
    ¿°Áõ¼º Ä¡Àº Áõ½Ä
  • inflammatory hyperplasia
    ¿°Áõ¼º °úÇü¼º, ¿°Áõ¼º Áõ½Ä
    ¿°Áõ¿¡ ÀÇÇÏ¿© »ý±â´Â °úÇü¼º.
  • lentiginous melanocytic hyperplasia(ÈæÀÚ¼º ¸á¶ó´Ñ ¼¼Æ÷ Áõ½Ä)

    lentiglobus

    °ø ¸ð¾ç ¼öÁ¤Ã¼, ±¸Çü ¼öÁ¤Ã¼
    ¼öÁ¤Ã¼ Àü¸éÀÌ ±¸ÇüÀ¸·Î µÇ¾î¼­, ¼öÁ¤Ã¼ÀÇ °î¸éÀÌ °úÀåµÇ¾î º¸ÀÌ´Â °Í.
  • papillary hyperplasia
    À¯µÎ»ó Áõ½Ä, À¯µÎ Áõ½Ä
    1. ±¹¼ÒÀû ÀÚ±Ø, ºÒ·®ÇÑ ±¸°­ À§»ý, °¨¿°¿¡ ÀÇÇØ ¹ß»ýµÇ´Â »óÇÇÀÇ ´Ù¹ß¼º À¯µÎ»ó µ¹Ãâ. 2. ±¸°³ À¯µÎÁ¾ÁõÀ̶ó°íµµ ÇÑ´Ù. ÀÇÄ¡ ÇϹæ Á¡¸·¿¡ »ý±ä Ä­µð´ÙÁõÀº °æ±¸°³°¡ ÀÌ·¯ÇÑ Áõ½Ä¼º Á¶Á÷ ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â ÀڱؿøÀÌ µÈ´Ù.
  • perforating hyperplasia
    õ°ø¼º Áõ½Ä
  • pseudocarcinomatous hyperplasia
    °¡¼º ¾ÏÁ¾¼º Áõ½Ä
  • salt-losing adrenal hyperplasia
    ¿°·ù ¼Ò½Ç¼º ºÎ½Å Áõ½ÄÁõ
  • total hyperplasia
    Àüü °ú´Ù Çü¼º
  • American cutaneous Leishmaniasis
    ¾Æ¸Þ¸®Ä« ÇǺΠ¸®½´¸¶´Ï¾Æº´
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
lymphoma, mucosa-associated lymphoid tissue Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire malt tissue as a result of an immunologically mediated disorder.
(12 Dec 1998)
adrenal hyperplasia <pathology> A condition of diffuse enlargement of the adrenal glands.
Origin: Gr. Plassein = to form
(27 Sep 1997)
adrenal hyperplasia, congenital A group of inherited disorders of adrenal steroidogenesis, the physical expression of which varies with the sex of the patient, the severity of the congenital enzyme defect, and the age at which the defect makes its presence felt. The most common form, the simple virilizing form, is due to a 21-hydroxylase deficiency. There is also a salt-losing form (a more complete 21-hydroxylase deficiency), a hypertensive form (11-hydroxylase deficiency), a 17-hydroxylase deficiency form, a desmolase deficiency form, and a 3-beta-hydroxysteroid deficiency form.
(12 Dec 1998)
angiofollicular mediastinal lymph node hyperplasia Solitary masses of lymphoid tissue containing concentric perivascular aggregates of lymphocytes, occurring usually in the mediastinum or hilar region of young adults; similar changes have been reported outside the mediastinum and, if associated with interfollicular sheets of plasma cells, may progress to lymphoma or plasmacytoma.
Synonym: angiofollicular mediastinal lymph node hyperplasia, Castleman's disease.
(05 Mar 2000)
angiolymphoid hyperplasia with eosinophilia Solitary or multiple benign cutaneous nodules comprised of immature and mature vascular structures intermingled with endothelial cells and a varied infiltrate of eosinophils, histiocytes, lymphocytes, and mast cells.
(12 Dec 1998)
atypical melanocytic hyperplasia Proliferation of melanocytes showing nuclear atypicality, especially as scattered single cells high in the epidermis; interpreted by some pathologists as malignant melanoma in situ.
(05 Mar 2000)
basal cell hyperplasia Increase in the number of cells in an epithelium resembling the basal cells.
(05 Mar 2000)
benign giant lymph node hyperplasia Solitary masses of lymphoid tissue containing concentric perivascular aggregates of lymphocytes, occurring usually in the mediastinum or hilar region of young adults; similar changes have been reported outside the mediastinum and, if associated with interfollicular sheets of plasma cells, may progress to lymphoma or plasmacytoma.
Synonym: angiofollicular mediastinal lymph node hyperplasia, Castleman's disease.
(05 Mar 2000)
benign prostatic hyperplasia <urology> A benign enlargement of the prostate gland begins normally after age 50 years probably secondary to the effects of male hormones. If significant enlargement occurs, it may pinch off te urethra making urination difficult or impossible.
See: urinary retention.
Origin: Gr. Plassein = to form
(06 Aug 1998)
verrucous hyperplasia A non-invasive precursor of verrucous or squamous carcinoma of the oral mucosa, occurring in the elderly, characterised by sharp or blunt upward papillary projections of squamous epithelium.
(05 Mar 2000)
giant lymph node hyperplasia Large benign, hyperplastic lymph nodes. The more common hyaline vascular subtype is characterised by small hyaline vascular follicles and interfollicular capillary proliferations. Plasma cells are often present and represent another subtype with the plasma cells containing IgM and IgA.
(12 Dec 1998)
gingival hyperplasia Non-inflammatory enlargement of the gingivae produced by factors other than local irritation. It is characteristically due to an increase in the number of cells.
(12 Dec 1998)
cementum hyperplasia A regressive change of teeth characterised by excessive development of secondary cementum on the tooth surface. It may occur on any part of the root, but the apical two-thirds are most commonly affected.
(12 Dec 1998)
congenital adrenal hyperplasia <endocrinology> A genetic disorder present at birth characterised by a deficiency of the hormones aldosterone and cortisol and an overproduction of male sex hormones (androgens). In males this may manifest as enlarged penis, small testes and early development of masculine characteristics. In females features include ambiguous genitalia, failure to menstruate, deep voice and excessive hair.
Origin: Gr. Plassein = to form
(27 Sep 1997)
congenital sebaceous hyperplasia Misnomer for nevus sebaceus.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á